Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1967 1
1971 1
1972 2
1974 1
1975 10
1976 5
1977 3
1978 5
1979 1
1980 5
1981 11
1982 14
1983 13
1984 14
1985 9
1986 7
1987 9
1988 6
1989 7
1990 8
1991 10
1992 5
1993 11
1994 8
1995 13
1996 8
1997 13
1998 9
1999 4
2000 3
2001 2
2002 14
2003 15
2004 14
2005 15
2006 29
2007 39
2008 36
2009 48
2010 74
2011 66
2012 75
2013 84
2014 112
2015 135
2016 110
2017 135
2018 145
2019 165
2020 194
2021 233
2022 204
2023 190
2024 83

Text availability

Article attribute

Article type

Publication date

Search Results

2,067 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hm non hodgkin lymphoma (183 results)?
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH. Cheson BD, et al. J Clin Oncol. 2018 Aug 1;36(22):2259-2266. doi: 10.1200/JCO.2017.76.3656. Epub 2018 Mar 27. J Clin Oncol. 2018. PMID: 29584548 Clinical Trial.
Purpose To perform an updated analysis of the randomized phase III GADOLIN trial in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated with obinutuzumab (GA101; G) and bendamustine (B). Patients and Methods Patients with histologically d …
Purpose To perform an updated analysis of the randomized phase III GADOLIN trial in patients with rituximab-refractory indolent non- …
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.
Scordo M, Flynn JR, Gonen M, Devlin SM, Parascondola A, Tomas AA, Shouval R, Brower J, Porter DL, Schuster SJ, Bachanova V, Maakaron J, Maziarz RT, Chen AI, Nastoupil LJ, McGuirk JP, Oluwole OO, Ip A, Leslie LA, Bishop MR, Riedell PA, Perales MA. Scordo M, et al. Blood Adv. 2023 Sep 26;7(18):5579-5585. doi: 10.1182/bloodadvances.2023010302. Blood Adv. 2023. PMID: 37522731 Free PMC article.
Using data from a multicenter consortium, we estimated fludarabine exposure (area under the curve [AUC]) using a population pharmacokinetic (PK) model in 199 adult patients with aggressive B-cell non-Hodgkin lymphomas who received commercial axicabtagene ciloleucel …
Using data from a multicenter consortium, we estimated fludarabine exposure (area under the curve [AUC]) using a population pharmacokinetic …
Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial.
Alexander S, Aupérin A, Bomken S, Csóka M, Kazanowska B, Chiang AK, Andres M, Uyttebroeck A, Burke GAA, Zsiros J, Pillon M, Bollard CM, Mussolin L, Verdu-Amoros J, Neven B, Barkauskas DA, Wheatley K, Patte C, Gross TG, Minard-Colin V; Children's Oncology Group; European Intergroup for Childhood Non-Hodgkin's Lymphoma. Alexander S, et al. Lancet Haematol. 2023 Jun;10(6):e445-e457. doi: 10.1016/S2352-3026(23)00062-5. Epub 2023 Apr 21. Lancet Haematol. 2023. PMID: 37094596 Clinical Trial.
BACKGROUND: Survival of children and adolescents with high-risk, mature B-cell non-Hodgkin lymphoma is improved by the addition of rituximab to chemotherapy. ...METHODS: The Inter-B-NHL Ritux 2010 trial was an international, open-label, randomised, phase 3 tr …
BACKGROUND: Survival of children and adolescents with high-risk, mature B-cell non-Hodgkin lymphoma is improved by the …
Ethylene oxide emissions and incident breast cancer and non-Hodgkin lymphoma in a US cohort.
Jones RR, Fisher JA, Medgyesi DN, Buller ID, Liao LM, Gierach G, Ward MH, Silverman DT. Jones RR, et al. J Natl Cancer Inst. 2023 Apr 11;115(4):405-412. doi: 10.1093/jnci/djad004. J Natl Cancer Inst. 2023. PMID: 36633307 Free PMC article.
We constructed 2 metrics at 3, 5, and 10 km: 1) distance between residences and EtO-emitting facilities, weighted by the proportion of time the home was downwind of each facility, and 2) distance-weighted, wind direction-adjusted average airborne emissions index (AEI=[lbs EtO/km2 …
We constructed 2 metrics at 3, 5, and 10 km: 1) distance between residences and EtO-emitting facilities, weighted by the proportion of time …
Reproduction patterns among non-Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway: A population-based matched cohort study.
Entrop JP, Weibull CE, Smedby KE, Jakobsen LH, Øvlisen AK, Glimelius I, Marklund A, Larsen TS, Holte H, Fosså A, Smeland KB, El-Galaly TC, Eloranta S. Entrop JP, et al. Br J Haematol. 2023 Aug;202(4):785-795. doi: 10.1111/bjh.18938. Epub 2023 Jun 16. Br J Haematol. 2023. PMID: 37325886
Previous studies concerning reproductive patterns among non-Hodgkin lymphoma (NHL) survivors are scarce and those available have reported conflicting results. ...Hazard ratios (HRs) were estimated using Cox regression. Males and females diagnosed with aggress …
Previous studies concerning reproductive patterns among non-Hodgkin lymphoma (NHL) survivors are scarce and those avail …
Prognostic value of the albumin-bilirubin score in patients with non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis.
Cheng W, Duan L, Xu J, Shu Y, Qiu H, Yin G. Cheng W, et al. Front Immunol. 2023 May 17;14:1162320. doi: 10.3389/fimmu.2023.1162320. eCollection 2023. Front Immunol. 2023. PMID: 37266439 Free PMC article.
This study aimed to assess the prognostic value of pretreatment albumin-bilirubin (ALBI). We retrospectively analyzed 168 non-Hodgkin lymphoma-associated secondary hemophagocytic lymphohistiocytosis (NHL-sHLH) patients with hepatic injuries. ...Multivariable …
This study aimed to assess the prognostic value of pretreatment albumin-bilirubin (ALBI). We retrospectively analyzed 168 non-Hodg …
Autoimmune disease-associated non-Hodgkin's lymphoma-a large retrospective study from China.
Hu S, Zhou D, Wu Y, Zhao Y, Wang S, Han B, Duan M, Li J, Zhu T, Zhuang J, Cao X, Cai H, Feng J, Zhang Y, Zhang F, Zeng X, Zhao Y, Wang Q, Zhang W. Hu S, et al. Ann Hematol. 2019 Feb;98(2):445-455. doi: 10.1007/s00277-018-3515-2. Epub 2018 Oct 29. Ann Hematol. 2019. PMID: 30370485
The incidence and clinical implications of autoimmune diseases (ADs) in patients with non-Hodgkin's lymphoma(NHL) remain unclear. The aim of this study was to examine the prevalence of ADs in NHL and define the clinical characteristics and prognosis of AD-ass …
The incidence and clinical implications of autoimmune diseases (ADs) in patients with non-Hodgkin's lymphoma(NHL) remai …
Cardiac non-Hodgkin's lymphoma: clinical characteristics and trends in survival.
Gordon MJ, Danilova O, Spurgeon S, Danilov AV. Gordon MJ, et al. Eur J Haematol. 2016 Nov;97(5):445-452. doi: 10.1111/ejh.12751. Epub 2016 Mar 30. Eur J Haematol. 2016. PMID: 26935129
OBJECTIVES: The purpose of this study was to describe the clinical characteristics and outcomes in cardiac non-Hodgkin's lymphoma (NHL). METHODS: A retrospective analysis of 94 cases of NHL with biopsy-proven cardiac involvement in PubMed between 1990 and 201 …
OBJECTIVES: The purpose of this study was to describe the clinical characteristics and outcomes in cardiac non-Hodgkin's ly …
Comparison of Primary B/NKT Non-Hodgkin Lymphomas in Nasopharynx, Nasal Cavity, and Paranasal Sinuses.
Peng J, Qiu J, Cheng D, Rao Y, Mao M, Qiu K, Li J, Chen F, Liu F, Liu J, Mu X, Yu W, Zhang W, Xu W, Zhao Y, Ren J. Peng J, et al. Otolaryngol Head Neck Surg. 2023 May;168(5):1107-1118. doi: 10.1002/ohn.194. Epub 2023 Feb 8. Otolaryngol Head Neck Surg. 2023. PMID: 36939485
OBJECTIVE: We aimed to compare clinical and survival differences between B-cell (B-NHL) and NKT-cell non-Hodgkin lymphomas (NKT-NHL) located in the nasal cavity (NC), nasopharynx, and paranasal sinuses, which are always categorized as one sinonasal type. ...Addition …
OBJECTIVE: We aimed to compare clinical and survival differences between B-cell (B-NHL) and NKT-cell non-Hodgkin lymphomas (NK …
Risk and outcome of non-Hodgkin lymphoma among classical Hodgkin lymphoma survivors.
Xavier AC, Armeson KE, Hill EG, Costa LJ. Xavier AC, et al. Cancer. 2013 Sep 15;119(18):3385-92. doi: 10.1002/cncr.28194. Epub 2013 Jun 24. Cancer. 2013. PMID: 23797978 Free PMC article.
BACKGROUND: Survivors of classical Hodgkin lymphoma (cHL) are at an increased risk of developing secondary non-Hodgkin lymphomas (sNHLs). ...Patients with indolent B-cell sNHL had a worse overall survival compared with their dnNHL counterparts (hazards …
BACKGROUND: Survivors of classical Hodgkin lymphoma (cHL) are at an increased risk of developing secondary non-Hodgk …
2,067 results